Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Business & Industry
- GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
- Merck initiates first clinical trial of TLR7 and 8 inhibitor as a potential treatment for severe symptoms of COVID-19 infection
- Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US
- Pfizer and BioNTech announce early positive data from an ongoing Phase 1/2 study of mRNA-based vaccine candidate against SARS-CoV-2
- Lilly begins world's first study of a potential COVID-19 antibody treatment in humans
Research & Development
- Neutralizing antibodies in the battle against COVID-19
- Remdesivir can save more lives where ICUs are overwhelmed
- Using Epo against COVID-19
- Newer variant of COVID-19-causing virus dominates global infections
- Researchers identify multiple molecules that shut down SARS-Cov-2 polymerase reaction
- Whole-town study reveals more than 40% of COVID-19 infections had no symptoms
- Even in the worst COVID-19 cases, the body launches immune cells to fight back
Conferences & Events
- Wearable Injectors and Connected Devices Conference 2020
- Preparing for the new world of drug safety: Embracing cloud and AI
- Pre-filled Syringes San Francisco Conference 2020
- Oligonucleotide Therapeutics and Delivery Conference 2020
- Pre-Filled Syringes West Coast 2021
- Pre-Filled Syringes East Coast Conference 2020
- SMi's 4th Annual Pharmaceutical Microbiology West Coast
Regulatory Affairs
- FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines
- FDA announces first of its kind pilot program to communicate patient reported outcomes from cancer clinical trials
- FDA revokes emergency use authorization for chloroquine and hydroxychloroquine
- Global regulators commit to cooperate on observational research in the context of COVID-19
- FDA takes new actions to accelerate development of novel prevention, treatment options for COVID-19